Study Name:
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults with Severe Eosinophilic Asthma
Targeted Disease(s):
Asthma
Purpose of Study:
The purpose of this study, EXHALE-3, is to assess the efficacy and safety of Dexpramipexole, an oral eosinophil maturation inhibitor, in patients ≥12 years of age with inadequately controlled severe eosinophilic asthma (GINA Step 4 or 5) and a history of exacerbations. The primary endpoint of this study is the annualized rate of asthma exacerbations.
Study Dates:
March 27, 2023 - July 30, 2026
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Areteia Therapeutics
Contact:
EXHALE Recruiting: 888-584-9281
[email protected]
ClinicalTrails.gov Identifier:
NCT05813288
